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Abstract
Periostin, also called osteoblast-specific factor 2 (OSF-2), is a multifunctional glycoprotein that belongs to the 
group of matricellular proteins. Due to its characteristic molecular structure containing integrin-binding domains, 
periostin is capable of binding to multiple integrin receptors (avb3, avb5, a6b4), thus affecting the regulation 
of the intracellular signaling pathways associated with protein kinases PI3K/AKT and focal adhesion kinase 
(FAK). This protein thus plays a role in the adhesion process, in the migration of many cells, and importantly, 
epithelial-mesenchymal transition of cancer cells. Periostin also participates in the processes of angiogenesis and 
lymphangiogenesis, metastases of cancer cells, and remodeling of the extracellular matrix. Increased expression 
of periostin has been observed in various tumor types, including breast, NSCLC, colorectal, pancreatic, prostate, 
and ovarian cancers, as well as tumors of the head and neck, and glioblastomas. Many groups have recently re-
ported on periostin’s key role in tumor progression, which suggests that periostin can be considered a potential 
therapeutic target. (Folia Histochemica et Cytobiologica 2015, Vol. 53, No. 2, 120–132)
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Abbreviations: Aa — amino acids, AKT/PKB — seri-
ne-threonine protein kinase, BMP-2 — bone morpho-
genetic protein 2, BIC — bicalutamide, CAFs — can-
cer-associated fibroblasts, CRC — colorectal cancer, 
CSCs — cancer stem cell, CTR — C-terminal region, 
D2-40 — podoplanin, DHT — dihydrotestosterone, 
ECM — extracellular matrix, ECs — endothelial cells, 
EGFR — epidermal growth factor receptor, EMT — 
epithelial-mesenchymal transition, EOC — epithelial 
ovarian cancer tissues, ER — estrogen receptor, F8RA 
— factor 8 related antigen/von Willebrand factor, FAK 
— focal adhesion kinase, 5-FU — 5-fluorouracil, FGF-1 
— fibroblast growth factor 1, GSCs — glioblastoma 
stem cells, IDC — invasive ductal breast carcinoma, 
IHC — immunohistochemistry, LCM — laser capture 
microdissection, LMVD — lymphatic vessel densi-
ty, LPA — lysophosphatidic acid, MMPs — matrix 
metalloproteinases, MVD — microvessel density, 
NSCLC — non-small-cell lung cancer, OSCC — oral 
squamous-cell carcinoma, OSF-2 — osteoblast-speci-
fic factor 2, PDGF — platelet-derived growth factor, 
PFS — progression-free survival, PI3K — phospha-
tidylinositol 3-kinase, PIP2 — phosphatidylinositol 
4,5-diphosphate, PIP3 — phosphatidylinositol 3,4,5-tri-
phosphate, POSTN — periostin, PR — progesterone 
receptor, PTEN — phosphatase and tensin homolog, 
RT-PCR — real-time PCR, SPARC — secreted pro-
tein acidic and rich in cysteine, TGF-b — transforming 
growth factor beta, TMA — tissue microarray, TAMs 
— tumor-associated macrophages,TSP-1, TSP-2 — 
thrombospondin 1 and 2, Twist-basic helix — loop-helix 
(bHLH) transcription factor, VEGF-A — vascular 
endothelial growth factor A, VEGF-C — vascular 
endothelial growth factor C, VEGFR — vascular en-
dothelial growth factor receptor, WB — western blot, 
a-SMA — alpha smooth muscle actin
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Introduction
Periostin (POSTN) is a homodimeric glycoprotein 
with a molecular weight of about 93.3 kDa, com-
posed of about 836 aa [1, 2]. POSTN is a protein 
produced and secreted by the fibroblasts as a com-
ponent of the extracellular matrix (ECM) where it 
is involved in regulating intercellular adhesion [3, 4]. 
POSTN, originally named Osteoblast-Specific Factor 2 
(OSF-2), was first identified in 1993 as a putative 
cell adhesion protein for preosteoblasts in a mouse 
osteoblastic MC3T3-E1 cell line [1, 2, 4–6]. Like 
osteopontin, tenascin-C, thrombospondin 1 and 2 
(TSP-1, TSP-2), and cysteine-rich acidic secretory 
proteins such as SPARC (Secreted Protein Acidic 
and Rich in Cysteine), it belongs to the group of so-
called matricellular proteins [7]. These proteins are 
secreted into the extracellular matrix, but seem not to 
play an essential structural role. They rather modulate 
the basic functions of cells by interacting with their 
specific receptors, hormone receptors, proteases and 
other molecules [8].
Human POSTN is encoded by a gene POSTN 
located on the 13 chromosome (13q13.3), while in 
mice it is located on chromosome 3 [2, 7, 9]. Analysis 
of the sequence shows a high degree of conservation 
between the species: human and murine POSTN 
have 89.2% identity for the entire protein molecule, 
and 90.1% identity for the mature form. In turn, the 
C-terminal region of the protein is less conserved at 
85.5% [1, 2, 9]. The POSTN gene in humans and mice 
has 23 exons [2, 9]. 
POSTN has a characteristic structure (Figure 1) 
consisting of four main domains, namely an N-termi-
nus (encoded by exon 1) containing a signal peptide 
(SP), a cysteine-rich EMI domain (exons 2 and 3) 
made up of approximately 75 amino acids, and 
a tandem of four homologous FAS1 domains (exons 
3–14). The FAS1 domain is a structural homolog of 
an insect cell adhesion protein fasciclin I and acts as 
ligand for cell membrane integrins. The FAS1 domain 
consists of about 150 amino acids, each containing 
a single recognition site of the enzyme gamma-car-
boxylase. The C-terminal region (CTR) of POSTN 
(exons 15–23) consists of a hydrophilic domain. The 
N-terminal region regulates cell function by binding 
to integrins of the cell membrane via its FAS domains. 
The C-terminal region of the protein regulates the 
cell–matrix organization and interactions by binding 
the ECM proteins such as collagen type I and type V, 
fibronectin, tenascin-C, glycosaminoglycans (e.g. 
heparin), and POSTN itself [2, 5, 10].
Figure 1. Schematic presentation of the structure of periostin gene and periostin protein isoforms. The periostin gene con-
tains signal peptide (SP), the small cysteine-rich domain (EMI domain), the tandem repeat of 4 FAS1 domains, and the 
carboxyl-terminal region (CTR). Four periostin isoforms are derived from the alternative splicing of the gene’s C-terminal 
region. Figure composed according to Nuzzo et al. [2], modified
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It is believed that as a result of an alternative mRNA 
splicing, 8 isoforms of POSTN arise, of which only 
four have been sequenced: isoform 1 or OSF-2OS 
(full-length splice variant with all exons), isoform 2 
or OSF-2p1 (exon 17 and 18 are absent), isoform 3 or 
PLF (exon 17 and 21are absent) and isoform 4 (exon 
17, 18, and 21 are absent) [2] (Figure 1). POSTN 
isoforms are composed of 751–836 amino acids, and 
have molecular masses from 83 to 93 kDa [2, 11]. The 
individual isoforms have been identified in various 
tissues: isoform 1 in human osteosarcomas, isoform 2 
in the placenta, isoform 3 in epithelial ovarian carci-
noma, and isoforms 2 and 4 in both the normal tissue 
and cancerous tissue of the urinary bladder [1, 2, 
12–14]. It is therefore believed that the expression of 
the POSTN isoforms is tissue-specific. The existence 
of the alternatively spliced forms of POSTN is well 
known [13, 15], but the functional role of the various 
isoforms in the process of progression and metastasis 
of cancer cells is still unclear.
The presence of POSTN has been observed in 
a variety of normal organs and tissues, including the 
mammary gland, lung, thyroid, skin, placenta, ovary, 
as well as periosteum and periodontal ligaments [5, 6, 
10, 16–20]. This glycoprotein plays an important role 
in the physiological process of epithelial–mesenchymal 
transition (EMT), which is necessary for the proper 
development of the embryo [20]. It is also involved in 
the formation and maintenance of the normal struc-
ture of bones and teeth [5] and in the development 
of the heart (atrioventricular valves) [21]. It has been 
demonstrated that POSTN plays a significant role in 
the fibrillogenesis of collagen [22], cell adhesion, and 
wound healing [7]. Periostin also interacts with the 
ECM proteins such as fibronectin, tenascin-C, and 
type V collagen, taking part in the process of ECM 
remodeling [9]. POSTN participates in myocardial 
remodeling after myocardial infarction and also in the 
pulmonary vascular remodeling process [23–25].
The role of periostin in the development  
and progression of tumors
For the last few years, numerous studies have descri-
bed the role of POSTN in the process of oncogenesis 
(Figure 2). The exact mechanisms responsible for the 
effect of POSTN on the progression of cancer and its 
metastasis are still the subject of an intense research. 
Numerous studies have confirmed the increased 
expression of POSTN that accompanies the forma-
tion of metastases [9, 10, 26–29]. The formation of 
metastases requires proteolytic activity of tumor 
cells, degradation of ECM, migration capacity, and 
stimulation of angiogenesis. 
Periostin was shown to bind to the integrins avb3, 
avb5, and a6b4, promoting the recruitment of the 
epidermal growth factor receptor (EGFR) and the 
activation of the Akt/PKB and FAK-mediated signa-
ling pathways. POSTN-activated signaling pathways 
promote cell survival, angiogenesis, and resistance 
to hypoxia-induced cell death [2, 4, 9, 10]. POSTN 
probably exerts its pro-tumorigenic effect not only 
through its binding to the cell membrane integrins and 
the consequent activation of intracellular pathways 
which determine an enhanced invasiveness, but also 
acting on the ECM fibrillogenesis. Considering that 
alterations in the ECM components of the tumor 
microenvironment have a remarkable impact on can-
cer invasiveness, it is possible that POSTN promotes 
an ECM re-organization that supports invasion and 
metastasis (Figure 2) [10].
It is believed that one of the main mechanisms 
responsible for the invasion and metastasis of cancer 
cells is also the process of epithelial-mesenchymal 
transition [30]. EMT is characterized by the loss of 
the expression of the markers of epithelial cells such 
as E-cadherin, and by increased expression of me-
senchymal cell markers such as vimentin, fibronectin, 
N-cadherin, alpha smooth muscle actin (a-SMA), as 
well as increased activity of matrix metalloproteinases 
(MMPs) like MMP-2, MMP-3 and MMP-9, associa-
ted with invasive phenotype [31]. In result, cancer 
cells acquire the capacity to migrate and invade the 
surrounding stroma [30]. As has been shown in many 
studies, EMT may be initiated by signaling pathways 
activated by tyrosine and serine-threonine kinase acti-
vity receptors (e.g., PI3K, EGFR, and c-KIT, which in 
turn activate the ras-raf-MEK-MAPK pathway) [30]. 
Numerous reports have indicated that POSTN is 
one of the main factors affecting the regulation of 
the intracellular pathway associated with phosphati-
dylinositol 3-kinase (PI3K) and the serine-threonine 
protein kinase AKT/PKB, playing an important role 
in the regulatory mechanisms involved in EMT, with 
processes of invasion and metastases (Figure 2) [10, 
29, 32]. In the first stage of PI3K/AKT signaling path-
way, the tyrosine kinase activity receptor, activated 
by binding of the ligand, activates PI3K, which con-
verts phosphatidylinositol 4,5-diphosphate (PIP2) to 
phosphatidylinositol 3,4,5-triphosphate (PIP3). PIP3 
contributes to the recruitment of the kinase Akt to 
the cell membrane, where it is activated due to the 
phosphorylation of threonine and serine residues. 
The activated Akt enhances the survival of tumor 
cells by inhibiting apoptosis while promoting cell 
proliferation and regulating cell ability to migrate and 
invade [33–35]. Additionally, it has been shown that 
PI3K and Akt are involved in the stimulation of EMT 
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in the breast cancer cells, either immediately upon 
activation by TGF-b or indirectly, upon activation by 
the receptors of epidermal growth factor (EGF) or 
platelet-derived growth factor (PDGF) [36].
POSTN was shown to be not only a marker of 
EMT, but to be itself an inducer of this phenome-
non [37, 38]. Yan et al. [37] have demonstrated that 
ectopic expression of POSTN in tumorigenic but non-
-metastatic 293T cells can induce EMT and promote 
invasion and metastasis in vivo. The upregulation of 
POSTN expression was accompanied by the upregu-
lation of vimentin, fibronectin, and active MMP-9, 
while the expression of E-cadherin and N-cadherin 
was unaltered [37]. POSTN signaling pathway in 293T 
cells seems to require interaction with avb5 integrin 
and recruitment of EGFR [37]. In turn, Kim et al. [38] 
found that upregulation of Akt phosphorylation 
and Snail by POSTN is involved in the regulation of 
E-cadherin and the invasiveness of prostate cancer 
cells. These data suggest that POSTN may play an 
important role in the progression of cancer.
The role of periostin in angiogenesis  
and lymphangiogenesis
Studies in recent years have indicated that POSTN 
plays a significant role in tumor progression, both in 
the stimulation of angiogenesis, which involves the 
formation of new vessels from the endothelial cells of 
existing vessels, and in the recruitment of endothelial 
Figure 2. Diagram showing the role of periostin in the process of carcinogenesis. Periostin binds to integrins and activates 
the Akt/PKB-, and the FAK-mediated signaling pathways, enhancing tumor invasion and metastasis. The isoforms resul-
ting from the alternative splicing of the C-terminal region of periostin gene bind extracellular matrix molecules and affect 
the general organization of the extracellular matrix. Figure composed according to Morra et al. [10], modified
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progenitor cells from the blood stream, their prolife-
ration, differentiation, and migration to the locations 
of developing blood vessels [39–41].
POSTN stimulates adhesion and migration of endo-
thelial cells (ECs), among others, through interactions 
with the integrin avb3 [4, 9, 10]. It has been observed 
that ECs have particularly high expression of avb3 
when stimulated by growth factors and in inflammation, 
wound healing, and tumors’ blood vessels [42]. Mutual 
interactions between POSTN and vascular endothelial 
growth factor (VEGF), which plays a key role in the 
initiation of physiological and pathological angiogene-
sis, lymphangiogenesis, and vasculogenesis have been 
documented [43, 44]. The activation of the VEGF li-
gand-receptor complex presents one of the best-studied 
pathways of angiogenesis in cancer. VEGF binds to its 
receptor (VEGFR) on endothelial cells, stimulating 
growth, proliferation, and cell migration, which in turn 
leads to the formation of new blood vessels [43].
In an in vitro model, Shao et al. [44] showed that 
the angiogenic activity of POSTN correlated with 
the increased expression of the VEGF receptor 
(VEGF-R2) by endothelial cells through an integrin 
avb3-focal adhesion kinase (FAK)-mediated signaling 
pathway (Figure 2) [44]. The activation of FAK pro-
motes invasiveness, and Akt/PKB, a serine/threonine 
protein kinase, is now recognized as one of the most 
central regulators of cell survival and proliferation [45]. 
Akt functions as a key mediator for transducing 
extracellular and intracellular signals and is positively 
regulated by PI3-kinase and negatively by phosphatase 
and tensin homolog (PTEN) [10, 45–47].
In breast cancer, Puglisi et al. [48] reported a signi-
ficant correlation between the expression of POSTN 
and VEGF-A and the VEGF-R1 and VEGF-R2 
receptors. Similarly, Siriwardena et al. [26] showed 
that in oral squamous-cell carcinoma (OSCC) blood 
vessel density of POSTN-positive tumors was higher 
than those of POSTN-negative tumors. Interestingly, 
recombinant POSTN enhanced capillary formation in 
vitro in a concentration-dependent manner [26]. These 
observations point to the proangiogenic and prolife-
ration-stimulating potential of POSTN. In turn, the 
in vivo experimental work of Bao et al. [29] revealed 
that the blood vessel density of the metastatic tumors 
derived from the POSTN-overexpressing CX-1NS 
cells was approximately 5-fold higher than in the rare 
micrometastases of the control cells. These results 
strongly suggest that POSTN secreted by tumor cells 
may act in a paracrine manner to induce tumor an-
giogenesis during metastatic growth [29]. Similarly, 
in non-small-cell lung cancer (NSCLC), Takanami et 
al. [49] showed a correlation between the presence of 
POSTN and the microvessel density, assessed on the 
basis of the expression of the antigen F8RA (Factor 8 
Related Antigen/von Willebrand Factor).
Besides the important role played by POSTN 
in angiogenesis, it is believed that this protein can 
also stimulate lymphangiogenesis in tumors. The 
development of lymphatic vessels and the subsequent 
involvement of lymph node by cancer cells is one of 
the main stages of tumor progression [50, 51]. Despite 
significant progress in the assessment of tumor lym-
phangiogenesis, the mechanism of the formation of 
new lymphatic vessels in tumor tissue is still relatively 
unknown, compared to the more accurately described 
tumor angiogenesis. Kudo et al. [52] showed a signi-
ficant correlation between the expression of POSTN 
and the factor regulating the growth of lymphatic 
vessels, VEGF-C. In addition, in an in vitro model 
they showed that, independently of VEGF-C, POSTN 
can induce the growth of lymphatic endothelial cells 
by activating the tyrosine kinases Src and the protein 
kinase Akt. It was reported that lymphangiogenesis 
could be promoted by POSTN itself and by the POSTN- 
-induced upregulation of VEGF-C [52]. Similarly, 
Takanami et al. [49] demonstrated in non-small-cell 
lung cancer a significant relationship between the 
presence of POSTN and the lymphatic vessel den-
sity (LMVD); the lymph vessels were labeled with 
podoplanin (D2-40), a glycoprotein produced by the 
vascular endothelium of lymph vessels. POSTN may 
be an important factor in the initiation and stimulation 
of both the angiogenesis and lymphangiogenesis in 
tumors, but further studies are needed to thoroughly 
elucidate these mechanisms.
Regulation of periostin expression  
in the process of carcinogenesis
Several studies have shown that the expression of 
POSTN can be regulated in vitro by specific growth fac-
tors, including TGF-b1 and bone morphogenetic protein 2 
(BMP-2) [5, 53]. In view of the fact that TGF-b is one 
of the factors that promote EMT and the formation of 
distant metastases, it is believed that POSTN may act 
as mediator of the pro-metastatic activity of TGF-b1 in 
certain cancer types [9]. It has also been demonstrated 
that the expression of POSTN can be regulated by the 
basic helix-loop-helix (bHLH) transcription factor Twist, 
which is an inducer of the EMT process [54]. Oshima 
et al. found that Twist was associated with the POSTN 
promoter sequence in undifferentiated preosteoblasts 
and stimulated POSTN expression [54]. Moreover, the in-
creased expression of fibroblast growth factor 1 (FGF-1) 
and angiotensin 2 in response to anaerobic conditions 
in pulmonary arterial smooth muscle cells led to the 
increased expression of POSTN through the activation 
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of the PI3-K/Akt/p70S6K, Ras/MEK1/2/ERK1/2, and 
Ras/p38MAPK signaling pathways [16]. The expression 
of POSTN was found to be regulated by Wnt-3 in mouse 
mammary epithelial cells [55] and interleukins, such as 
IL-4 and IL-13 in lung fibroblasts [18].
Most of the data on the mechanisms that regulate 
the expression of POSTN in different cell types are 
derived from the studies of embryonic development. 
Further experiments to identify the mechanisms 
which control POSTN expression in the process of 
tumorigenesis are thus required.
Periostin expression in different  
types of tumors
Increased expression of POSTN has been observed in 
various tumor types, including breast [44, 48, 56–58], 
NSCLC [27, 49, 59–62], colorectal [19, 29, 63], sto-
mach cancers [64–68], pancreatic [32, 69], prostate 
[70–75], ovarian cancer [76–79], and glioblastomas 
[80–82] (Table 1).
Periostin expression in breast cancer
One of the best studied cancers in terms of POSTN 
expression is breast cancer. Expression of POSTN 
was mainly localized in the tumor stroma and in the 
cytoplasm of the breast cancer cells (Figure 3).
Puglisi et al. [48] reported significantly increased 
expression of POSTN in breast cancer, as compared 
to the normal breast tissues. Using immunohistoche-
mistry (IHC), POSTN presence was mainly observed 
in the cytoplasm of the tumor cells (57%). However, 
in 12% of cases, nuclear expression of POSTN was 
noted. A significantly positive correlation has been 
shown between nuclear expression of POSTN and 
tumor size, progesterone (PR) and expression of 
estrogen receptors (ER), VEGF-A, VEGF-R1 and 
VEGF-R2, suggesting that the nuclear localization of 
this protein may induce relevant biological effects [48]. 
A significant correlation was found between the cy-
toplasmic localization of POSTN and the size of the 
tumor and the expression of VEGF-A, progesterone 
and VEGFR-1 receptors. However, the cytoplasmic 
expression of POSTN did not correlate with the stage 
of the tumor, nodal status, ER or HER-2 receptor 
status, or the expression of the proliferative antigen 
Ki-67 [48]. The expression of POSTN was also analy-
zed in the soluble fraction of nuclear and cytoplasmic 
proteins in MCF-7 and MDA-468 cell lines of breast 
cancer using IHC and Western blot (WB) methods [48]. 
In both cell lines, POSTN was localized either in 
nuclear and cytoplasmic fractions. In addition, in 
MCF-7 cells the nuclear localization of POSTN was 
also shown by transfection of a vector expressing 
a GFP-POSTN chimeric protein. Furthermore, 
real-time PCR (qRT-PCR) showed a 50-fold lower 
expression of POSTN mRNA in the MCF-7 cell line 
of breast cancer in relation to MDA-468 cell, which 
was consistent with the results of IHC [48]. A signi-
ficant role of POSTN in breast cancer angiogenesis 
has been demonstrated, showing a positive correlation 
between the presence of POSTN and the expression 
of proangiogenic factor VEGF-A and its receptors 
VEGF-R1 and VEGF-R2 [48]. Similar observations 
concerning the participation of POSTN in the process 
of angiogenesis were reported by Shao et al. [44], who 
used cell lines overexpressing POSTN, such as 293T 
cell line derived from human kidney epithelial cells, 
B16F1 the highly invasive mouse melanoma cell line 
and MDA-MB-231 the metastatic human breast can-
cer line. Tumor cell lines engineered to overexpress 
POSTN showed a phenotype of an accelerated growth 
and angiogenesis as xenografts in immunocompromi-
sed animals [44]. In vitro studies showed that POSTN 
promoted angiogenesis via the up-regulation of 
VEGF-R2 expression in endothelial cells through an 
integrin avb3-FAK-mediated signaling pathway [44]. 
Moreover, by the use of the gene arrays analysis, an 
average 20-fold higher expression of POSTN mRNA 
in samples of breast cancer as compared to the normal 
breast tissue was observed [44]. These results were 
also confirmed by the WB and IHC methods, which 
showed strong expression of the investigated proteins 
predominantly in the cytoplasm of tumor cells [44]. 
In later studies, Zhang et al. [56] showed increased 
POSTN levels and significantly increased POSTN 
mRNA expression in cancerous tissue compared 
to normal breast tissue. In contrast to the results 
of Puglisi et al. [48], the authors observed POSTN 
localization predominantly in the space surrounding 
the tumor cells and in a few cases in the membrane 
and cytoplasm of tumor cells [56]. They also demon-
strated the strong expression of POSTN in tumor cell 
metastases to lymph nodes and a positive correlation 
between the expression of POSTN and the stage of 
breast cancer, which indicates the significant role of 
POSTN in the progression of this type of cancer [56].
In more recent study, Xu et al. [57] assessed the 
expression of POSTN in breast cancer stem cells 
(CSCs), identified by the presence of specific markers 
such as CD44+ and CD24– (CD44+/CD24– cells). They 
showed that CSC cells were more likely to generate 
new tumors in mice and cell microspheres that were 
deficient in NOD/SCID compared to the control 
group. 
The authors showed significantly increased expres-
sion of POSTN in CSCs compared to the CD44– tumor 
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Table 1. Expression of periostin in gastric, pancreatic, prostate and ovarian cancers, and in glioblastomas
Cancer type Evaluation method Periostin expression/function Reference
Gastric  
cancer
Microarray data sets Higher POSTN mRNA expression in cancer tissues from stage II, III 
and IV gastric cancer compared to normal tissues. Correlation between 
POSTN expression and tumor progression
[64]
In situ hybridization POSTN mRNA expression in cancer-associated fibroblasts (CAFs), but 
not in tumor cells themselves
In vitro POSTN enhanced the growth of OCUM-2MLN and OCUM-12 diffuse
-type gastric cancer cell lines
IHC Stromal POSTN expression increased with stage progression in both 
intestinal-type and diffuse-type gastric cancer. CAFs are the primary so-
urce of POSTN, which facilitates tumor cell invasion by inducing EMT
Gastric  
cancer
IHC Periglandular POSTN expression was lower in primary gastric cancers 
compared to normal gastric mucosa. Its expression was downregulated  
in metastatic lymph nodes compared with matched primary tumor 
tissues, and was negatively associated with tumor stage [65]
In vitro
RT-PCR
Epithelial cell-derived POSTN functions as a tumor-suppressor through 
stabilizing p53 and E-cadherin proteins via the Rb/E2F1/p14ARF/Mdm2 
signaling pathway
Gastric  
cancer
In vitro POSTN confers protection against cisplatin or 5-FU in SGC-7901 
gastric cancer cells, through activating of the Akt pathway and inhibiting 
the p53 expression. POSTN may be a potential therapeutic target in 
gastric cancer
[66]
Gastric  
cancer
RT-PCR Increased POSTN mRNA expression in gastric cancer tissues
[67]IHC Higher POSTN expression in gastric cancer tissues and metastatic 
lymph nodes compared to normal gastric tissues and benign gastric 
diseases. Correlation with the TNM stage of gastric cancer
Gastric  
cancer
In vitro POSTN elevates cell proliferation, invasion, and epithelial–mesenchy-
mal transition in nicotine-induced gastric cancer
[68]
Pancreatic 
cancer
In situ hybridization Presence of POSTN mRNA exclusively in the cytoplasm of tumor
[32]
IHC Expression of POSTN only in the tumor stroma but not within cancer
ELISA Higher levels of serum POSTN in pancreatic cancer patients, as compa-
red to a healthy group
In vitro Promotes invasiveness by stimulating motility and enhances the survival 
of tumor cells exposed to hypoxic conditions
Pancreatic 
cancer
IHC Correlation between neoplastic stromal expression of POSTN and 
depth of invasion and lymph node metastasis. Stromal or epithelium 
expression of POSTN was associated with poor survival
[69]
In vitro Promotes proliferation and invasiveness of pancreatic cancer cells. 
POSTN may be involved in the progression and invasion of pancreatic 
cancer
Prostate  
cancer
IHC Over-expressed in stromal and epithelial compartment. Stromal expres-
sion correlated with the degree of malignancy. Correlation between 
epithelial expression and degree of malignancy, pT status
[70]
Prostate  
cancer
IHC High stromal expression was associated with shorter survival. A low 
epithelial score correlated with shorter PSA-free survival [71]
POSTN might represent a novel prognostic marker for prostate cancer
Prostate cancer IHC Stromal expression correlated with the degree of malignancy [72]
Prostate cancer
Liquid chromatography- 
-tandem mass spectrometry, 
ELISA
Higher expression of POSTN in aggressive prostate tumor compared to 
both non-aggressive tumor and normal prostate tissue. POSTN expres-
sion may be associated with aggressive prostate cancer
[73]
Prostate cancer
In vivo Silencing expression by RNA interference inhibited proliferation and 
migration of LNCaP cell in vivo
[74]
Prostate cancer
In vitro POSTN transfection stimulated LNCaP cell growth. POSTN transfec-
tion did not interfere with the stimulatory effect of dihydrotestosterone 
(DHT); bicalutamide (BIC) had an inhibitory effect on cell proliferation
[75]
Æ
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Figure 3. Expression of periostin in invasive ductal breast carcinoma. Periostin was located in the tumor stroma (arrows) 
(A) and in the cytoplasm (arrowheads) of the breast cancer cells (A, B). Original magnifications: A — ×200; B — ×400. 
For the immunohistochemical demonstration of periostin Autostainer Link 48 (Dako, Glostrup, Denmark) with the visu-
alization system of EnVisione FLEX, High pH (Dako) was used. Periostin was detected by the incubation of deparaffini-
zed sections with primary anti-periostin antibody (rabbit polyclonal antibody, Novus Biologicals, Littleton, CO, USA)
Table 1 (cont.). Expression of periostin in gastric, pancreatic, prostate and ovarian cancers, and in glioblastomas
Ovarian cancer
cDNA microarray Correlation between expression of POSTN and higher tumor stage and 
cancer recurrence
[76]
IHC
Northern blot
Higher expression of POSTN mRNA and protein levels in ovarian 
tumors compared to normal/benign tumor samples
In vitro 
In vivo
Overexpression of POSTN in OVCAR-3 and OV2008 cell lines has no 
effect on the proliferation. Promotes intraperitoneal tumor metastatic 
growth in immunodeficient mice. Induces tumor angiogenesis and inhi-
bits tumor cell apoptosis
Ovarian cancer
In vivo Antibody directed against POSTN (MZ-1) inhibits the development of 
primary tumors derived from the periostin-expressing ovarian cancer 
cell line A2780
[77]
Ovarian cancer
IHC Expression of POSTN in cancer-associated stromal fibroblasts, but not 
in cancer cells. The 5-year survival rate was better in patients with nega-
tive POSTN expression than in those with positive POSTN expression. 
POSTN expression in cancer stroma may have prognostic relevance in 
ovarian cancer
[78]
In vitro Lysophosphatidic acid (LPA)-induced expression of POSTN in cancer
-associated stromal cells
Ovarian cancer
microarrays Overall survival was significantly shorter for patients with tumors 
expressing genes associated with POSTN/TGFBI compared to patients 
with tumors expressing genes associated with ESR1/WT1
[79]
Glioblastoma
Immunofluorescence
IHC
Glioblastoma stem cells (GSCs) recruit and activate tumor-associated 
macrophages (TAMs) by secreting POSTN
[80]
Glioblastoma
RT-PCR
IHC
POSTN expression levels correlated with tumor grade and recurrence, 
and inversely with survival, in all grades of human glioma. POSTN 
upregulation may contribute to invasion and stem cell phenotypes
[81]
Glioblastoma
IHC Expression of POSTN in the cytoplasm and membrane of glioma cells. 
The cases with highly expressed POSTN protein attained a significantly 
poor postoperative disease-specific survival. POSTN was detected as the 
independent prognostic factor
[82]
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cells, CD44+/CD24+ tumor cells, and unsorted cells [57]. 
The immunohistochemical staining revealed that 
the expression of POSTN mainly occurred in the cy-
toplasm and plasma membrane of the breast cancer 
cells. In the prognostic analysis, patients with cancer 
expressing POSTN, along with age, histological grade, 
lymph node metastasis, and triple-negative breast 
cancer, were shown to attain a poorer disease-specific 
survival than those with no or low expressed POSTN. 
In addition, multivariate analysis demonstrated that 
high POSTN expression may be an independent pro-
gnostic factor in breast cancer [57].
Periostin expression in non-small-cell  
lung cancer (NSCLC)
As with other cancers of epithelial origin, non-small-
-cell lung cancer (NSCLC) was examined for POSTN 
expression [27, 49, 59, 61, 62].
Using the technique of in situ RNA hybridization, 
Sasaki et al. [27] observed a strong expression of 
POSTN at the tumor periphery of lung carcinoma tissue. 
However, no presence of POSTN was found within the 
tumor tissue. In addition, no significant differences 
were found in the concentration of POSTN in the 
blood serum of NSCLC patients or healthy controls. 
Furthermore, no significant correlation was found 
between the serum concentrations of POSTN and 
gender, N status (lymph node metastasis), T (tumor 
size) and bone metastasis. However, the subgroup of 
the NSCLC patients with high POSTN serum level 
had significantly poorer survival than the patients with 
normal POSTN concentration [27]. These observa-
tions indicate that a high concentration of POSTN 
in the serum may be a negative prognostic factor for 
NSCLC. Takanami et al. [49] found significant cor-
relation between POSTN expression determined by 
immunohistochemistry and tumor size, lymph node 
metastasis, disease stage, and lymphatic invasion. 
A significant positive correlation was also found between 
POSTN expression and microvessel density and den-
sity of lymphatic microvessels (LMVD). Moreover, 
the five-year survival rates were better in patients 
with negative tumor POSTN expression than in those 
with positive POSTN expression [49]. It thus seems 
that the presence of POSTN expression is associated 
with an increased risk of tumor progression, and 
worse prognosis for NSCLC patients. In contrast, 
other authors showed presence of POSTN in either 
stroma or tumor epithelia [59]. There was a significant 
correlation seen between POSTN expression and 
male gender, higher stage, higher pT category, and 
larger tumor size. The expression of POSTN in the 
stroma of the tumor also correlated positively with 
tumor relapse. The univariate analysis confirmed 
that high expression of POSTN in the tumor stroma 
correlated with decreased progression-free survival 
(PFS) [59]. Similarly, Morra et al. [60] showed in-
creased expression of POSTN both on the mRNA 
and protein levels in NSCLC tissue, as compared to 
normal lung tissue with significantly higher levels in 
the adenocarcinoma compared to the squamous cell 
subtype. The localization of POSTN was observed 
mainly in the cytoplasm of tumor epithelia, in stromal 
cells, and in the extracellular matrix. A significant cor-
relation was found between the expression of POSTN 
in tumor cells, and with higher tumor grade and lar-
ger tumor size. Using the technique of laser capture 
 microdissection (LCM), the authors established that 
both tumor epithelia and stromal cells can be a source 
of POSTN production in NSCLC [60]. It was shown 
that POSTN may promote proliferation and migration 
of A549 lung cancer cells by inducing the expression 
of vimentin and N-cadherin, key mesenchymal cell 
markers of epithelial–mesenchymal transition (EMT), 
and downregulating E-cadherin expression [61]. In 
addition, POSTN concentration was evaluated in the 
serum of and compared to that of a healthy group. 
Consistent with the results obtained by Sasaki et al. [27], 
in NSCLC patients no significant correlations between 
the serum concentration of POSTN and patients’ 
gender, age, pathological type, TNM stage, lymph 
node status, tumor size (G) and invasiveness were 
found [61]. However, in a more recent report, the 
same group showed significantly increased expression 
of POSTN on the protein, but not at the mRNA, 
level in NSCLC patients compared to the normal 
lung tissue with high POSTN immunoreactivity in the 
mesenchymal areas, but not in the cancer cells [62]. 
The use of multivariate analysis demonstrated that the 
high expression of POSTN may be an independent 
prognostic factor in NSCLC playing an important 
role in the progression of NSCLC [62].
Periostin expression in colorectal cancer (CRC)
Periostin expression has also been studied in colorec-
tal cancer (CRC). Bao et al. [29], using the Northern 
blot technique, demonstrated the increased expres-
sion of POSTN in over 80% of human primary colon 
cancer samples. It was found that the high level of 
POSTN significantly correlated with the presence of 
liver metastases. The results were also confirmed by 
IHC. The presence of POSTN was observed mainly 
in areas containing cancer cells of the primary colon 
tumors and metastatic tumors in the liver. In contrast, 
POSTN was undetectable in normal colon mucosa. 
Furthermore, POSTN expression was at a statistically 
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higher level in the hepatic metastases relative to the 
colon primary tumors [29]. These observations indica-
te that high level of POSTN expression may be closely 
associated with metastasized colon tumors. The au-
thors also showed that POSTN interacts with the avb3 
integrin and induces a signaling pathway involving 
AKT/PKB protein kinase, thereby facilitating of 
metastatic growth of colon cancer [29]. Likewise, 
Tai et al. [19] found that POSTN was upregulated in 
colorectal cancer (CRC) and its liver metastasis. Also 
in vitro studies suggest that POSTN promotes growth 
and cell proliferation in CRC. It was also shown that 
exposing MIP101 colorectal cancer cells to anti-POSTN 
antibodies activates apoptotic mechanisms and 
increases the effectiveness of chemotherapy [19]. 
The authors of the studies point to the potential role 
of POSTN as a therapeutic target for patients with 
CRC [19]. Given the important role of POSTN in 
the formation of metastases, it was proposed [19, 29] 
that this glycoprotein may be a potential therapeutic 
target in metastatic colorectal cancer.
On the other hand, Xiao et al. [63] evaluated the 
effect of POSTN on the chemoresistance of colorectal 
cancer cell lines (SW480 and HT-29) treated with 
oxaliplatin and 5-fluorouracil (5-FU) [63]. It was 
found that silencing mRNA expression of POSTN 
using siRNA suppressed the expression of survivin, 
a protein that inhibits apoptosis in CRC cell lines. 
POSTN induced the chemoresistance of CRC cells 
by activating the PI3K/AKT/surviving signaling path-
ways [63].
The presence of POSTN has been also studied 
in other types of tumors as summarized in Table 1. 
Conclusions
POSTN, as a multifunctional protein, plays an impor-
tant role in tumor development and is upregulated 
in a wide variety of malignant neoplasms such as 
breast, colon, lung, pancreatic, ovarian, gastric, head 
and neck, thyroid and prostate cancer, as well as in 
glioblastomas. In most tumors POSTN expression 
is observed mainly in the tumor stroma and in the 
cytoplasm of cancer cells; however, not in all cases. 
POSTN binding to cell membrane integrins activates 
the Akt/PKB- and FAK-mediated signaling pathways 
which lead to increased cell survival, angiogenesis, 
invasion and metastasis. It has been suggested that 
high POSTN expression may be an independent pro-
gnostic factor in breast cancer and in non-small-cell 
lung cancer. POSTN expression is associated with an 
increased risk of progression and invasion of pancre-
atic cancer. Many data suggest that POSTN may be 
considered as a marker of the progression of prostate 
as well as ovarian cancer, and glioblastomas. Numero-
us studies have indicated that POSTN expression may 
serve as a valuable prognostic tool in oncology. It is 
hoped that the evaluation of POSTN levels in blood 
or its tissue expression by immunohistochemistry or 
real-time PCR may be helpful in rapid identification 
of highly invasive tumors and create an opportunity 
to develop new targeted therapies.
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